MiMedx Group Inc. (MDXG)
7.93
-0.04 (-0.50%)
At close: Mar 21, 2025, 3:59 PM
8.08
1.87%
After-hours: Mar 21, 2025, 05:36 PM EDT
-0.50% (1D)
Bid | 7.74 |
Market Cap | 1.17B |
Revenue (ttm) | 349.73M |
Net Income (ttm) | 42.52M |
EPS (ttm) | 0.28 |
PE Ratio (ttm) | 28.32 |
Forward PE | 29.23 |
Analyst | Buy |
Ask | 8.23 |
Volume | 430,391 |
Avg. Volume (20D) | 572,474 |
Open | 7.92 |
Previous Close | 7.97 |
Day's Range | 7.88 - 8.00 |
52-Week Range | 5.47 - 10.14 |
Beta | 1.97 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its produc...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2008
Employees 837
Stock Exchange NASDAQ
Ticker Symbol MDXG
Website https://www.mimedx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MDXG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 51.32% from the latest price.
Stock ForecastsNext Earnings Release
MiMedx Group Inc. is scheduled to release its earnings on Apr 29, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+23.56%
MiMedx Group shares are trading higher after the c...
Unlock content with
Pro Subscription
4 months ago
+20.39%
MiMedx Group shares are trading higher after the company reported better-than-expected Q3 financial results.